Ind-Swift Laboratories Limited (NSE:INDSWFTLAB)
India
· Delayed Price · Currency is INR 135.00
-2.26 (-1.65%)
Mar 6, 2026, 3:29 PM IST
Ind-Swift Laboratories Revenue
Ind-Swift Laboratories had revenue of 1.51B INR in the quarter ending December 31, 2025, with 1,641.05% growth. This brings the company's revenue in the last twelve months to 5.94B, up 28.12% year-over-year. In the fiscal year ending March 31, 2025, Ind-Swift Laboratories had annual revenue of 5.62B, down -67.13%.
Revenue (ttm)
5.94B
Revenue Growth
+28.12%
P/S Ratio
2.00
Revenue / Employee
4.77M
Employees
1,246
Market Cap
11.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 5.62B | -11.47B | -67.13% |
| Mar 31, 2024 | 17.09B | 4.93B | 40.56% |
| Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
| Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
| Mar 31, 2021 | 9.07B | 1.07B | 13.44% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sakar Healthcare | 2.31B |
| Jagsonpal Pharmaceuticals | 2.82B |
| Beta Drugs | 3.85B |
| Windlas Biotech | 8.68B |
| Indoco Remedies | 17.60B |
| Sigachi Industries | 4.85B |
| Solara Active Pharma Sciences | 12.55B |
| Orchid Pharma | 8.11B |
Ind-Swift Laboratories News
- 19 days ago - Ind-Swift Laboratories steps up export push with Rs 40 crore Jammu facility upgrade - Business Upturn